pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Kisunla · news · pharmadog
← back to Kisunla
News mentioning Kisunla
19
stories
10h
Actinogen’s sole drug fails pivotal Alzheimer’s study, sinking stock 80%
biospace
1d
CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s
biospace
1d
Biogen’s tau therapy drives bigger benefits in 2-year Alzheimer’s update
fiercebiotech
2d
CTAD 2026: AriBio’s Alzheimer’s candidate slows cognitive decline as monotherapy
biospace
3d
AriBio’s oral Alzheimer’s drug meets monotherapy goal in phase 3 as Fosun weighs licensing option
fiercebiotech
3d
Alzheimer’s field looks beyond amyloid as biopharma converges at CTAD 2026
biospace
9d
London biotech Oyster harvests $60M for tau-targeting brain drugs
biopharma dive
13d
Opinion: STAT+: What it’s like to live with cognitively unimpaired Alzheimer’s disease
stat
21d
Eli Lilly scraps phase 2 Alzheimer's program after drug falls short of expectations
fiercebiotech
29d
Drug prices climb past $250K as US patients balk at the pharmacy
biospace
Oct 14, 26
Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit
biopharma dive
Oct 8, 26
Eli Lilly and the LA Dodgers: A tale of 2 dynasties
biospace
Sep 15, 26
Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech
fiercebiotech
Aug 31, 26
BMS’ neuro renaissance was built on back of Celgene mega-merger
biospace
Jul 30, 26
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
Jul 14, 26
Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs
biopharma dive
May 11, 26
STAT+: Pharmalittle: We’re reading about Medicare and Alzheimer’s drugs, estrogen patch shortages, and more
stat
May 11, 26
STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs
stat
Apr 30, 26
Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
biopharma dive